Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Select your origin of interest
Human LAG3 Protein expressed in CHO Cells - ABIN1344459
Huard, Prigent, Tournier, Bruniquel, Triebel: CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. in European journal of immunology 1995
Show all 6 Pubmed References
Human LAG3 Protein expressed in CHO Cells - ABIN1344460
Cappello, Triebel, Iezzi, Caorsi, Quaglino, Lollini, Amici, Di Carlo, Musiani, Giovarelli, Forni: LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. in Cancer research 2003
We show that the expression of LAG3 is highly induced in the lungs and particularly in the granulomatous lesions of macaques experimentally infected with mycobacterium tuberculosis.
thi study shows that LAG-3 directly modulates the size of the T cell response and support the use of LAG-3 blockade regimens to enhance CD8 (show CD8A Proteins)+ T cell responses
Study suggests that expression of the inhibitory receptors PD-1 (show PDCD1 Proteins) and LAG-3 on CD4 (show CD4 Proteins)(+) T cells and their reduced IL-2 (show IL2 Proteins) production are common characteristic features of Plasmodium infection.
An IL-27 (show IL27 Proteins)/Lag3 axis enhances Foxp3 (show FOXP3 Proteins)+ regulatory T cell-suppressive function and therapeutic efficacy.
LAG3 and PD1 (show PDCD1 Proteins) co-inhibitory molecules have roles in collaborating to limit CD8 (show CD8A Proteins)+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
Poxvirus-Based Active Immunotherapy with PD-1 (show PDCD1 Proteins) and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice.
Lymphatic endothelial cells (LECs) serve as an antigen reservoir for CD4 (show CD4 Proteins) T-cell tolerance, and MHC-II molecules on LECs are used to induce CD8 (show CD8A Proteins) T-cell tolerance via LAG-3.
LAG-3 expression on Tconv cells makes them more susceptible to Treg based suppression, and also regulates the development of a TH1 (show HAND1 Proteins) T-cell response.
LAG-3 exerts an important regulatory effect on autoimmunity.
Lag-3 is an important regulatory molecule involved in alloreactive T cell proliferation and activation after bone marrow transplantation.
these results define a strong synergy between the PD-1 (show PDCD1 Proteins) and LAG-3 inhibitory pathways in tolerance to both self and tumor antigens.
Data suggest that blocking LAG3-MHC class II interactions is a potential therapeutic target in chronic lymphocytic leukemia.
LAG-3 expression was correlated with expression of PD-1 (show PDCD1 Proteins) on TILs and expression of PD-L1 (show CD274 Proteins) on tumor cells. Higher expression of LAG-3 on TILs was significantly correlated with higher expression of PD-1 (show PDCD1 Proteins) on TILs and higher expression of PD-L1 (show CD274 Proteins) on tumor cells.
the upregulation of others syncytial molecules, including LAG3, CTLA4 (show CTLA4 Proteins), CD28 (show CD28 Proteins) and CD3 (show CD3 Proteins), assisting the formation of syncytia with APC (show APC Proteins) cells.
LAG3-expressing CD4 (show CD4 Proteins)(+)CD25 (show IL2RA Proteins)(-) T cells represent another regulatory immune cell type with potential to interfere with anti-tumor immunity.
Overexpression of lymphocyte activation gene-3 inhibits regulatory T cell responses in osteoarthritis
Egr2 (show EGR2 Proteins)-driven cell surface proteins LAG-3 and 4-1BB (show TNFRSF9 Proteins) can identify dysfunctional tumor antigen-specific CD8 (show CD8A Proteins)(+) TIL (show TLR1 Proteins).
our data indicate that the evaluation of stromal TILs remains the most reliable immune prognostic marker in TNBC, and support the clinical evaluation of anti-PD-1 (show PDCD1 Proteins)/PD-L1 (show CD274 Proteins) and anti-LAG-3 in a subset of patients with TNBC who have concurrent expression of both checkpoint receptors.
this review provides the translational rationale for targeting LAG3, as well as historical and current state of clinical trials utilizing LAG3 cancer immunomodulators
this study shows that LAG3 expressed on myeloid leukaemia cells possess the capacity to facilitate functional exhaustion in T helper cells
epigenetic modification on LAG-3 increased LAG-3(+) T cells and its immune regulatory roles in chronic osteomyelitis progression
Lymphocyte-activation protein 3 belongs to Ig superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4.
lymphocyte-activation gene 3
, lymphocyte-activation protein 3
, lymphocyte-activation protein 3-like
, lymphocyte activation gene 3 protein-like
, lymphocyte activation gene 3 protein
, lymphocyte activation gene 3